Diversion Control Division, US Department of Justice, Drug Enforcement Administration

Manufacturers Notice of Application - 2003

FR Doc 03-7826 [Federal Register: April 2, 2003 (Volume 68, Number 63)] [Notices] [Page 16089-16090] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr02ap03-132]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 14, 2003, Mallinckrodt, Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substance listed below:

Drug Schedule
Amphetamine (1100) II
Methamphetamine (1105) II
Methylphenidate (1724) II
Codeine (9050) II
Codeine-N-oxide (9053) I
Diprenorphine (9058) II

[[Page 16090]]

Drug Schedule
Etorphine HCl (9059) II
Dihydrocodeine (9120) II
Oxycodone (9160) II
Dihydromorphine (9145) I
Hydromorphone (9150) II
Difenoxin (9168) I
Diphenoxylate (9170) II
Benzoylecgonine (9180) II
Ecgonine (9180) II
Hydrocodone (9193) II
Heroin (9200) I
Levorphanol (9220) II
Meperidine (9230) II
Methadone (9250) II
Methadone intermediate (9254) II
Metopon (9260) II
Dextropropoxyphene, bulk (9273) II
Morphine (9300) II
Morphine-N-oxide (9307) I
Nicomorphine (9312) I
Normorphine (9313) I
Thebaine (9333) II
Opium extracts (9610) II
Opium fluid extract (9620) II
Norlevorphanol (9634) I
Opium tincture (9630) II
Opium, powdered (9639) II
Opium, granulated (9640) II
Levo-alphacetylmethadol (9648) II
Oxymorphone (9652) II
Alfentanil (9737) II
Sufentanil (9740) II
Fentanyl (9801) II
Tetrahydrocannabinols (7370) I

The firm plans to manufacture the controlled substances as analytical reference standards to be used internally and for sale to other companies.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Drug Operations Section, Domestic Drug Unit (ODOD) and must be filed no later than 60 days from publication.

Dated: March 14, 2003.

Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03-7826 Filed 4-1-03; 8:45 am]

BILLING CODE 4410-09-M

 

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Printing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility